Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a ...
Danaher Corporation is undervalued, with strong fundamentals, robust free cash flow, and 12.7% upside. Click here to read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback